Altis Labs
Altis Labs builds prognostic AI models (IPRO, IPRO-Δ) and the Nota platform, which predict patient survival and drug efficacy from longitudinal CT imaging in oncology trials. Its customers are biopharma companies and CROs, and it has worked with AstraZeneca on a Phase 3 lung cancer study (2025). Its models are trained on a multimodal oncology database of 500,000+ patient-years, built with cancer-centre partners. It raised a $6M seed round in 2023, and PitchBook lists a $25M Series A dated Sept 2026 (about $32M raised in total). The team is roughly 30 people.
Funding
Every round, secondary, debt facility or acquisition involving Altis Labs that AI Lounge tracks, newest first. Latest: Series A on Sep 17, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in